Moderna has out-licensed a rare disease drug candidate to Recordati, accepting $50 million upfront for an asset that could ...

BofA lifted its price target to $27 from $24 while keeping an 'Underperform' rating on the shares. ・The update followed the ...

Moderna (NasdaqGS:MRNA) announced a collaboration with Recordati to develop and commercialize mRNA-3927 for propionic ...

Moderna, Inc. stock is up ~60% YTD on cancer vaccine trial data, 2026 readouts, and 2025 financials. Click for this updated look at MRNA stock prospects.

Long-term follow-up data from a phase 2b trial of Moderna and MSD's mRNA-based vaccine against melanoma, intismeran autogene (mRNA-4157), show an impressive 49% reduction in the risk of disease ...

Moderna shares are down on Monday, pulling back following a recent report highlighting its latest cancer trial results.

Moderna Inc (NASDAQ:MRNA) shares are trading higher on Wednesday on continued momentum after the company's Tuesday update ...

CAMBRIDGE, MA / ACCESS Newswire / July 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on its investigational mRNA therapeutics have been accepted for presentation at the ...

The five-year results come from a phase 2b study that tested intismeran autogene in combination with Merck’s Keytruda in ...

Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent ...